Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy

Journal of Diabetes and its Complications

Volumn 24, Issue 1, 2010, Pages 9-19

  Zhao, Yang ^a   Ye, Wenyu ^a   Boye, Kristina S ^a   Holcombe, John H ^a   Hall, Jerry A ^a   Swindle, Ralph ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Comorbidity; Complication; Diabetes; Diabetic neuropathy; Health care charges

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT; PHARMACY; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM;

ADOLESCENT; ADULT; COHORT STUDIES; DEMOGRAPHY; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 70749155914     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2008.09.001     Document Type: Article

References (32)

1. Able S.L., Robinson R.L., Sterling K., Obenchain R., Davis M., and Swindle R.W. Utilization and costs of pain medications by patients with diabetic neuropathy. Presented at: Annual Meeting of the Academy of Managed Care Pharmacy. Denver, CO: April 20-25 (2005)
2. Argoff C.E., Cole B.E., Fishbain D.A., and Irving G.A. Diabetic peripheral neuropathic pain: Clinical and quality of life issues. Mayo Clinic Proceedings 81 (2006) S3-S11
3. Boulton A.J. Management of diabetic peripheral neuropathy. Clinical Diabetes 23 (2005) 9-15
4. Boulton A.J.M., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., and Ziegler D. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28 (2005) 956-962
5. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 329 (1993) 977-986
6. Dyck P.J.B., and Dyck P.J. Diabetic polyneuropathy. In: Dyck P.J., and Thomas P.K. (Eds). Diabetic neuropathy. 2nd ed. (1993), WB Saunders, Philadelphia, PA 255-278
7. Ekberg K., Brismar T., Johansson B.L., Lindström P., Juntti-Berggren L., Norrby A., Berne C., Arnqvist H.J., Bolinder J., and Wahren J. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30 (2007) 71-76
8. Gordois A., Scuffham P., Shearer A., Oglesby A., and Tobian J.A. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26 (2003) 1790-1795
9. Gore M., Brandenburg N.A., Hoffman D.L., Tai K.S., and Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. The Journal of Pain 7 (2006) 892-900
10. Greene D.A., Sima A.A.F., Feldman E.L., and Stevens M.J. Diabetic neuropathy. In: Rifkin H., Porte D., and Sherwin R. (Eds). Ellenberg and Rifkin diabetes mellitus (1997), Appleton and Lange, Stanford, CT 1009-1076
11. Hall G.C., Carroll D., Parry D., and McQuay H.J. Epidemiology and treatment of neuropathic pain: The UK primary care perspective. Pain 122 (2006) 156-162
12. Hamalainen H., Ronnemaa T., Halonen J.P., and Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: A population-based 7-year follow-up study. Journal of Internal Medicine 246 (1999) 97-103
13. Jensen M.P., Chodroff M.J., and Dworkin R.H. The impact of neuropathic pain on health-related quality of life. Neurology 68 (2007) 1178-1182
14. Johansson B.L., Borg K., Fernquist-Forbes E., Kernell A., Odergren T., and Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetes Medicine 17 (2000) 181-189
15. Kiziltan M.E., Gunduz A., Kiziltan G., Akalin M.A., and Uzun N. Peripheral neuropathy in patients with diabetic foot ulcers: Clinical and nerve conduction study. Journal of the Neurological Sciences 258 (2007) 75-79
16. Le T.K., Able S.L., and Lage M.J. Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Effectiveness and Resource Allocation (2006) 18
17. O'Brien J.A., Patrick A.R., and Caro J.J. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Services Research 3 (2003) 7
18. Pope G.C., Kautter J., Ellis R.P., Ash A.S., Ayanian J.Z., Lezzoni L.I., Ingber M.J., Levy J.M., and Robst J. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financing Review 25 (2004) 119-141
19. Ray J.A., Valentine W.J., Secnik K., Oglesby A.K., Cordony A., Gordois A., Davey P., and Palmer A.J. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Current Medical Research & Opinion 2 (2005) 1617-1629
20. Sima A.A. New insights into the metabolic and molecular basis for diabetic neuropathy. Cellular and Molecular Life Sciences 60 (2003) 1-20
21. Sima A.A. C-peptide and diabetic neuropathy. Expert Opinion on Investigational Drugs 12 (2003) 1471-1488
22. Sima A.A. Diabetic neuropathy in type 1 and 2 diabetes and the effect of C-peptide. Journal of the Neurological Sciences 220 (2004) 133-136
23. Sima A.A. Pathological mechanisms involved in diabetic neuropathy: Can we slow the process?. Current Opinion in Investigational Drugs 7 (2006) 324-337
24. Sima A.A., Zhang W., and Grunberger G. Type 1 diabetic neuropathy and C-peptide. Experimental Diabesity Research 5 (2004) 65-77
25. Sima A.A., Zhang W., Li Z.G., Murakawa Y., and Pierson C.R. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 53 (2004) 1556-1563
26. Stewart W.F., Ricci J.A., Chee E., Hirsch A.G., and Brandenburg N.A. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. Journal of Occupational and Environmental Medicine 49 6 (2007) 672-679
27. Sugimoto K., Murakawa Y., and Sima A.A. Diabetic neuropathy-A continuing enigma. Diabetes Metabolism Research Reviews 16 (2000) 408-433
28. Tesfaye S., Chaturvedi N., Eaton S.E.M., Ward J.D., Manes C., Ionescu-Tirgoviste C., Witte D.R., Fuller J.H., and EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. The New England Journal of Medicine 352 (2005) 341-350
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
30. Vileikyte L., Leventhal H., Gonzalez J.S., Peyrot M., Rubin R.R., Ulbrecht J.S., Garrow A., Waterman C., Cavanagh P.R., and Boulton A.J. Diabetic peripheral neuropathy and depressive symptoms. Diabetes Care 28 (2005) 2378-2383
31. Vinik A.I., Park T.S., Stansberry K.B., and Pittenger G.L. Diabetic neuropathies. Diabetologia 43 (2003) 957-973
32. Zhao Y., Ash A.S., Ellis R.P., Ayanian J.Z., Pope G.C., Bowen B., and Weyuker L. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Medical Care 43 (2005) 34-43